In this note we discuss the importance of oncology drugs for Pfizer. We have created an interactive dashboard ~ How Important Is Oncology For Pfizer’s Stock? Ibrance has been approved for the treatment of breast cancer, and is currently being tested in phase 3 for another three variants of breast cancer. Nearly 268,600 new cases of invasive breast cancer will be diagnosed in women in 2019, according to the American Cancer Society. In fact, oncology sales contribution is expected to increase from 11% currently to close to 20% by the end of our forecast period in 2025, led by its new compounds.

Source: Forbes March 18, 2019 16:30 UTC